MGL Modulators for Selective 2-AG Elevation With Fewer Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases and disorders associated with monoacylglycerol lipase (MGL) activity, such as neuroinflammation, neurodegenerative diseases, mood disorders, pain, and cancer, often have side effects due to the broad modulation of cannabinoid receptors, limiting their therapeutic efficacy.
Innovation Solution
Development of chemical entities that modulate MGL activity, including inhibitors, to selectively enhance 2-AG levels and attenuate proinflammatory cascades, thereby targeting specific brain regions and minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If broad cannabinoid receptor agonists are used to treat diseases associated with MGL activity, then therapeutic benefits are achieved, but side effects increase due to broad modulation of cannabinoid receptors
Solution Approach 1:
The patent segments the therapeutic approach by developing MGL-specific modulators that act selectively on monoacylglycerol lipase rather than broadly activating cannabinoid receptors. This segmentation allows targeting the specific enzymatic pathway responsible for 2-AG degradation without triggering widespread cannabinoid receptor effects, thereby maintaining therapeutic benefits while reducing side effects
Solution Approach 2:
The patent introduces MGL modulators as intermediary compounds that indirectly influence cannabinoid signaling by regulating 2-AG levels through enzyme modulation. These intermediaries (MGL modulators) provide controlled, indirect activation of the endocannabinoid system rather than direct receptor agonism, allowing for more selective and controllable therapeutic effects
2Reliability
If MGL activity is broadly modulated to enhance 2-AG levels, then therapeutic benefits for neuroinflammation and neurodegenerative diseases are achieved, but selectivity is reduced
Solution Approach 1:
The patent applies local quality by designing MGL modulators with specific molecular structures (compounds of Formula I and Formula II) that target the unique active site architecture of monoacylglycerol lipase. The compounds feature specific substituent patterns (R1-R6 groups) that confer selective binding to MGL rather than other lipid enzymes, enabling localized, selective modulation of 2-AG metabolism in relevant brain regions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The MGL modulators provide targeted therapeutic benefits for a range of conditions, including neuroinflammation, neurodegeneration, mood disorders, pain, and cancer, with reduced side effects compared to broad cannabinoid receptor agonists.
Implementation Method 1
Monoacylglycerol lipase (MGLL, also known as MAG lipase and MGL) is the serine hydrolase responsible for the degradation of 2-AG into arachidonic acid and glycerol
Data Source
AI summary
Fused compounds of Formula (I) and Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, bipolar disorder), cancers and eye conditions.Wherein R1, R2, R2a, R3, R3a, R4, and R4a are defined herein.